Radiofrequency Volumetric Thermal Ablation of Symptomatic Uterine Fibroids: The Acessa™ Procedure (pp. 175-194)
Authors: (Bruce B. Lee, Keith B. Isaacson and Michael P. Diamond, Halt Medical, Inc., Brentwood, California, US and others)
Abstract: Radiofrequency volumetric thermal ablation (RFVTA, the AcessaProcedure) is a new, promising laparoscopic, ultrasound-guided fibroid treatment modality that gained FDA clearance in November 2012. It has been studied in multiple clinical trials. Each trial demonstrated clinically and statistically significant bleeding reduction in patients with heavy menstrual bleeding; significant and durable symptom reduction and quality-of-life improvement regardless bulk, pain, or bleeding symptoms, early return to normal and work activities; and low rates of surgical re-intervention in an outpatient procedure. Ninety-eight percent of Acessa patients would recommend the treatment to a friend who had the same health problem. Surgeons in the various RFVTA studies learned the technique and elements of laparoscopic ultrasound and RFVTA before being proctored during initial cases; generally three proctored procedures were necessary before surgeons felt proficient with basic cases. We present a discussion of the development, features of and clinical outcomes following radiofrequency volumetric thermal ablation (RFVTA) of fibroids.
Open Access item.
Click below PDF icon for free download.
This is an Open Access item. Click above PDF icon for free download.